Platelet activation may be a factor in the bronchial hyperresponsiveness that characterises asthma. As hyperresponsiveness is increased at night, changes in platelet activation over 24 hours were related to the diurnal changes in peak expiratory flow and plasma catecholamine concentrations in five subjects with asthma and five normal subjects. The effect of muscarinic receptor blockade with intravenous atropine at 0400 hours on these measurements was also studied. Platelet activation, assessed as the ratio of p thromboglobulin to platelet factor 4, was highest when the peak expiratory flow rate was at its lowest in the asthmatic subjects. There was no correlation between platelet activation and plasma catecholamine concentrations. Intravenous atropine did not alter the ratio of p thromboglobulin to platelet factor 4, suggesting that parasympathetic activity is not the cause of the increased platelet activation at night.
Activated platelets have the ability to release potent bronchoconstrictor and vasoconstrictor substances such as thromboxanes, cyclic endoperoxidases, slow reacting substance, 5-hydroxytryptamine, and histamine.' Inhalation of antigen to which an asthmatic individual is sensitive causes platelet activation as measured by the release of the platelet specific proteins platelet factor 4 and # thromboglobulin into the circulation,24 though this has been disputed by some authors. 56 Platelet activating factor, which is released from many of the inflammatory cells found in asthmatic airways, causes bronchoconstriction, neutrophil and eosinophil chemotaxis, and increased vascular permeability only in the presence of platelets.7 When given by inhalation platelet activating factor in man may cause dose related bronchoconstriction and an increase in bronchial responsiveness, which may persist for one to four weeks in subjects who were previously normal.8 Platelet activation has therefore been implicated in the pathogenesis of the bronchial hyperresponsiveness that characterises asthma. Platelet activation has also been implicated in acute exacerbations of asthma910; but there is no information on whether platelet activation occurs at night, when bronchial hyperresponsiveness is at its highest and asthma at its worst."" Parasympathetic efferent pathways are implicated in the pathogenesis of nocturnal asthma,'4 but other factors operate in addition. We do not know whether platelets have functional acetylcholine receptors, which theoretically could link parasympathetic nervous activity and platelet activation. It is also possible that platelet activation contributes directly to noctumal asthma through the release of platelet activating factor and other mediators.
We have therefore studied the circadian rhythm of platelet activation, as measured by platelet factor 4 and ,B thromboglobulin, and related this to the circadian rhythms of peak expiratory flow and circulating concentrations of the catecholamines adrenaline, noradrenaline, and dopamine, which cause in vitro platelet activation."" '7 
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B-beta agonists; PEF-peak expiratory flow.
Methods

SUBJECTS
We studied five asthmatic subjects with a diurnal variation in peak expiratory flow of more than 20% and five normal non-smoking subjects. All had normal renal function (table) . Subjects were admitted to hospital for one day's acclimatisation and one study day. Xanthine derivatives were stopped for 48 hours before the study and no coffee or tea was allowed during the period in hospital. No asthmatic subject had been taking oral or inhaled corticosteroids for at least six months. Inhaled beta agonists and anticholinergic drugs were withheld for 10 hours before the study and throughout the study period.
SAMPLES AND PROCEDURES
The study started at 0400 hours, when the subject was woken and immediately recorded three peak expiratory flow measurements from a sitting position. Venepuncture was carried out with a 19G butterfly, with minimal trauma and avoidance of suction in the syringe. The first 10 ml of blood was taken into a syringe and transferred to an ice cooled lithium heparin tube for catecholamine analysis. The next 5 ml of blood was run down the side of an ice cooled test tube containing EDTA, theophylline, and prostaglandin E, to inhibit platelet activation. Blood in both tubes was mixed by gentle inversion. The platelet sample tube was kept in melting ice for 30 minutes before centrifugation."9 The catecholamine tube was centrifuged immediately. Both tubes were centrifuged at 2200 g and 4°C for 30 minutes. Aliquots of platelet poor plasma were removed from the middle layer of the supernatant plasma and both catecholamine and platelet aliquots stored at -70°C until they were assayed. The procedure was repeated at 0800, 1200, 1600, 2000, and 2400 h. During the day the subjects rested supine for one hour before samples were taken. An intravenous cannula was inserted after the 2400 h blood sample and at 0400 h an intravenous injection of 30 Mg/kg of atropine was given 30 minutes before the subject was wakened to block postganglionic muscarinic receptor activity. '4 We determined catecholamines radioenzymatically, using the There was a significant circadian rhythm (p < 0-01) for ,B thromboglobulin (peak value 0800 h) and for the ratio of ,B thromboglobulin to platelet factor 4 (peak value 0400 h). No circadian rhythm for platelet factor 4 was seen.
Plasma adrenaline showed a circadian rhythm (p < 0 05) with a peak at 1600 h and a trough at 0400 h; the other catecholamines did not show any significant circadian rhythm.
The peak expiratory flow of the asthmatic subjects showed a circadian rhythm (p < 0 05), with a peak of 433 1/min between 1200 and 2000 h and a trough of 350 1/min at 0400 h. The amplitude % mean of the rhythm was 24%. No rhythm in peak expiratory flow was seen in normal subjects (mean peak flow 598 1/min).
Atropine caused a rise in the peak expiratory flow rate of the asthmatic subjects at 0400 h from 108 1/min (p < 0-01) to 358 1/min. This did not significantly differ from the peak phase of expiratory flow seen between 1200 and 2000 h. In the normal subjects atropine caused a rise in PEF peak flow of 36 1/min at 0400 h (p < 0-01).
Atropine did not alter platelet activation as measured by platelet factor 4 and 3 thromboglobulin concentrations or their ratio, and also did not alter catecholamine concentrations (figs 1-3).
RELATION OF PLATELET ACTIVATION FACTORS TO OTHER VARIABLES
Platelet factor 4 and ,B thromboglobulin concentrations showed a correlation with each 
Results
No significant difference was found in the mean values for platelet factor 4, /3 thromboglobulin, adrenaline, noradrenaline or dopamine between normal and asthmatic subjects. Subsequent analyses therefore used the combined data from the two groups for these variables.
Mean peak expiratory flow was lower in the asthmatic subjects (392 1/min) than in the normal subjects (598 1/min; p < 0 01). rio is significantly higher at 0400 h, when peak flow is at its lowest.
Platelet activation, as measured by platelet aggregation, has been found to be increased in --Noradrenaline the morning in normal subjects.29 In our study we found peak platelet activation at times nol/lI--- Dopamine ranging from 0400 h for the ratio of f -Adrenaline thromboglobulin to platelet factor 4 to 0800 h for ft thromboglobulin. No circadian rhythm,
T~~~~owever, was seen for platelet factor 4. native explanation would be that the diurnal variation in adrenaline causes diurnal change in platelet activation and that this is a coincidental other (r = 0 6, p < 0 01), but neither was epiphenomenon. correlated with catecholamine concentration.
The diurnal variation in peak expiratory flow The correlations between the ratio of the was in phase with that of adrenaline. Alterplatelet specific proteins and adrenaline ations of plasma adrenaline within the (r = -071, p = 0 07) and noradrenaline physiological range have been shown to have a (r = -0-73, p = 0 06) were not quite sig-significant effect on bronchomotor tone in both nificant; but the correlation with PEF in the normal3' and asthmatic subjects.32 Although asthmatic patients was significant (r = -077, alterations in plasma dopamine have no direct p = 0 04).
bronchodilator action, dopamine has been shown to decrease the bronchial response to inhaled histamine,33 and may therefore have a Discussion permissive role in the control of bronchomotor In this study a circadian rhythm was detected tone. for adrenaline as in previous studies,'8 but not Parasympathetic nervous blockade with for dopamine and noradrenaline concentra-atropine abolished the nocturnal fall in peak tions, in contrast to previous data.2223 A cir-expiratory flow rate that occurred in the cadian rhythm in peak expiratory flow was seen asthmatic subjects, PEF values returning to in the asthmatic subjects,24 but not in the close to the peak values seen at 1600 h. These normal subjects. data confirm that parasympathetic pathways are Blood samples were taken 30 minutes after important in the pathogenesis of nocturnal intravenous atropine on the basis that maxi-asthma.'4 mum pulmonary and cardiac muscarinic recepOur studies suggest that platelet activation may be an aetiological factor in nocturnal asthma. We need further research, using other indexes of in vivo platelet activation and agents that inhibit platelet activation, for establishing causality.
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